Novogene(SH:688315)2023-10-24 16:00Financial Performance - The company's revenue for Q3 2023 was approximately ¥499.15 million, representing a decrease of 3.10% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was approximately ¥50.24 million, down 10.51% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was approximately ¥45.69 million, a decrease of 20.45% compared to the previous year[5]. - Basic and diluted earnings per share for Q3 2023 were both ¥0.13, reflecting a decrease of 7.14% compared to the same quarter last year[6]. - Total operating revenue for the first three quarters of 2023 reached ¥1,429,077,493.84, an increase of 4.7% compared to ¥1,364,823,824.09 in the same period of 2022[21]. - Net profit for the first three quarters of 2023 was ¥130,708,820.69, representing a 13.4% increase from ¥115,306,030.16 in the same period of 2022[23]. - Basic and diluted earnings per share for the first three quarters of 2023 were both ¥0.31, compared to ¥0.28 in the same period of 2022[24]. - The total profit for the first three quarters of 2023 was ¥144,027,975.47, compared to ¥123,421,002.78 in 2022, marking an increase of 16.7%[23]. - The company experienced a total comprehensive income of CNY 93,362,569.63 in Q3 2023, compared to CNY 44,042,887.67 in Q3 2022, reflecting a growth of 111.1%[34]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.02 billion, showing a slight decrease of 0.99% from the end of the previous year[6]. - The company's current assets totaled RMB 2,032,772,977.40, slightly up from RMB 2,018,065,556.96 at the end of 2022, indicating a growth of about 0.7%[17]. - The company's total liabilities decreased to RMB 918,457,442.08 from RMB 1,072,569,721.30, marking a reduction of about 14.4%[19]. - The total equity attributable to shareholders increased to RMB 2,083,140,668.85 from RMB 1,964,901,490.48, reflecting an increase of approximately 6%[19]. - The total assets as of September 30, 2023, amounted to CNY 2,314,796,142.67, a decrease from CNY 2,442,199,147.58 at the end of 2022[30]. - The total liabilities as of September 30, 2023, were CNY 491,576,573.94, a decrease from CNY 693,532,748.48 at the end of 2022[30]. Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 39.43% due to VAT refund impacts[9]. - Cash inflow from operating activities for the first three quarters of 2023 was ¥1,474,036,367.64, slightly up from ¥1,455,840,121.68 in 2022[26]. - The cash flow from operating activities for the first nine months of 2023 was CNY 204,792,280.07, a turnaround from a negative cash flow of CNY -131,339,776.54 in the same period of 2022[35]. - The net cash flow from operating activities was CNY 37,155,098.63, down from CNY 61,347,057.32 year-over-year[28]. - The cash flow from financing activities showed a net outflow of CNY -27,544,688.00 in Q3 2023, compared to CNY -32,101,977.78 in Q3 2022, indicating an improvement[36]. Research and Development - Research and development expenses for Q3 2023 amounted to approximately ¥41.56 million, an increase of 5.27% year-over-year, accounting for 8.33% of total revenue[6]. - Research and development expenses for the first three quarters of 2023 totaled ¥91,241,514.74, an increase from ¥87,826,057.16 in 2022, indicating a focus on innovation[21]. - Research and development expenses for the first three quarters of 2023 were CNY 41,544,982.76, down from CNY 52,809,206.07 in the same period of 2022[33]. Investment and Income - The company reported investment income of ¥15,636,983.34 for the first three quarters of 2023, significantly higher than ¥5,203,782.66 in the same period of 2022[21]. - The company reported a decrease in credit impairment losses, reporting a loss of ¥10,304,690.53 in 2023 compared to ¥17,436,968.88 in 2022, indicating improved asset quality[21]. - The company reported a net cash outflow from investing activities of CNY -244,775,672.35 in the first nine months of 2023, compared to CNY -152,412,706.07 in the same period of 2022[36]. Shareholder Information - The company reported a total of 6,081 common shareholders at the end of the reporting period[11].